丁型肝炎病毒感染的全球流行率、疾病进展与临床结局评估
该Meta分析采用随机效应模型,评估丁型肝炎病毒(HDV)的全球流行病学、按感染模式分层的疾病进展及临床结局。HDV感染者进展为肝硬化或肝细胞癌的风险显著高于HBV单一感染者。
要点
- HDV合并感染患者进展为肝硬化的OR为3.84(95%CI 1.79-8.24)。
- HDV感染平均5年内进展为肝硬化,10年内进展为肝细胞癌。
核心结论
- HDV全球疾病负担沉重,快速进展为严重肝病,需有效筛查、预防和治疗策略。
研究设计与样本
- 采用随机效应模型的Meta分析,进行数据合成,评估HDV全球流行病学、感染模式分层疾病进展和临床结局。
主要发现
- 暴发性肝炎、肝硬化和肝细胞癌的HBV患者中,HDV流行率分别为26.75%(95%CI 19.84-34.29)、25.77%(95%CI 20.62-31.27)和19.80%(95%CI 10.97-30.45)。
- HBV患者中,合并慢性肝病者相比无症状对照,HDV感染的OR为4.55(95%CI 3.65-5.67)。
- HDV合并感染患者比HBV单一感染者更易发生肝硬化,OR为3.84(95%CI 1.79-8.24)。
- HDV感染平均5年内进展为肝硬化,10年内进展为肝细胞癌。
临床怎么用
- 建议对HBV感染者进行HDV筛查,以识别高肝病进展风险人群。
- HDV合并感染者应加强肝病监测,警惕5年内肝硬化和10年内肝细胞癌风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis delta virus (HDV) coinfects with hepatitis B virus (HBV) causing the most severe form of viral hepatitis. However, its exact global disease burden remains largely obscure. We aim to establish the global epidemiology, infection mode-stratified disease progression, and clinical outcome of HDV infection. METHODS: We conducted a meta-analysis with a random-effects model and performed data synthesis. RESULTS: The pooled prevalence of HDV is 0.80% (95% confidence interval [CI], 0.63-1.00) among the general population and 13.02% (95% CI, 11.96-14.11) among HBV carriers, corresponding to 48-60 million infections globally. Among HBV patients with fulminant hepatitis, cirrhosis, or hepatocellular carcinoma, HDV prevalence is 26.75% (95% CI, 19.84-34.29), 25.77% (95% CI, 20.62-31.27), and 19.80% (95% CI, 10.97-30.45), respectively. The odds ratio (OR) of HDV infection among HBV patients with chronic liver disease compared with asymptomatic controls is 4.55 (95% CI, 3.65-5.67). Hepatitis delta virus-coinfected patients are more likely to develop cirrhosis than HBV-monoinfected patients with OR of 3.84 (95% CI, 1.79-8.24). Overall, HDV infection progresses to cirrhosis within 5 years and to hepatocellular carcinoma within 10 years, on average. CONCLUSIONS: Findings suggest that HDV poses a heavy global burden with rapid progression to severe liver diseases, urging effective strategies for screening, prevention, and treatment.
引用
- Miao Z, Zhang S, Ou X, et al. Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. J Infect Dis. 2020. PMID: 31778167. doi:10.1093/infdis/jiz633
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。